Volume | 400,000 |
|
|||||
News | - | ||||||
Day High | 0.000001 | Low High |
|||||
Day Low | 0.000001 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
MultiCell Technologies Inc (CE) | MCET | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.000001 | 0.000001 | 0.000001 | 0.000001 | 0.000001 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1 | 400,000 | $ 0.000001 | $ 0.36 | - | 0.000001 - 0.0001 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
09:30:30 | 400,000 | $ 0.000001 | USD |
MultiCell Technologies Inc (CE) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 5.00k | 5.00B | 600.00k | $ - | $ - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
27.59k | $ - | - | - | - |
MultiCell Technologies (CE) News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MCET Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.000001 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 0.000001 | 0.000001 | 0.000001 | 0.000001 | 277,727 | 0.00 | 0.0% |
3 Months | 0.000001 | 0.0001 | 0.000001 | 0.0000912 | 1,234,758 | 0.00 | 0.0% |
6 Months | 0.000001 | 0.0001 | 0.000001 | 0.0000667 | 847,388 | 0.00 | 0.0% |
1 Year | 0.000001 | 0.0001 | 0.000001 | 0.0000586 | 636,520 | 0.00 | 0.0% |
3 Years | 0.0001 | 0.0083 | 0.000001 | 0.0023436 | 46,706,983 | -0.0001 | -99.0% |
5 Years | 0.0001 | 0.0083 | 0.000001 | 0.002256 | 26,827,885 | -0.0001 | -99.0% |
MultiCell Technologies (CE) Description
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease, fatigue of MS and cancer. The majority owned Xenogenics subsidiary is developing a drug-eluting cardiac stent. |